A G D, Janardanan-Nair B, B R V. Podoplanin expression in oral potentially malignant disorders and oral squamous cell carcinoma. J Clin Exp Dent. 2017;9(12):e1418-24.

 

doi:10.4317/jced.54213

http://dx.doi.org/doi:10.4317/jced.54213

 

References

1. Warnakulasuria S. Living with oral cancer; epidemiology with particular reference to prevalence and life style changes that influence survival. Oral Oncol. 2010;46:407-10.
https://doi.org/10.1016/j.oraloncology.2010.02.015
PMid:20403722

 

2. Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et al. Inrtraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol. 1995; 80;188-91.
https://doi.org/10.1016/S1079-2104(05)80201-X

PMid:7552884

 

3. Pitiyage G, Tilakaratne WM, Tavassoli M, Warnakulasuriya S. Molecular markers in oral epithelial dysplasia; review. J Oral Pathol Med. 2009;38:737-52.
https://doi.org/10.1111/j.1600-0714.2009.00804.x
PMid:19903246

 

4. Reibel J. Prognosis of oral premalignant lesions; significance of clinical, histopathological and molecular biological characteristics. Crit Rev Oral Biol Med. 2008;14:47-62.
https://doi.org/10.1177/154411130301400105

PMid:12764019

 

5. Schepman S, Gorosky M, Lozada F. Oral leukoplakia and malignant transformation; a follow up study of 257 patients. Cancer. 1984;53:563-8.
https://doi.org/10.1002/1097-0142(19840201)53:3<563::AID-CNCR2820530332>3.0.CO;2-F

PMid:6537892

 

6. Silverman S, Bhargava K, Smith LW, Malaowalla AM. Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers of Gujarat, India. Cancer. 1976;38:1790-5.
https://doi.org/10.1002/1097-0142(197610)38:4<1790::AID-CNCR2820380456>3.0.CO;2-I

PMid:1033027

 

7. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2006;42:461-74.
https://doi.org/10.1016/j.oraloncology.2005.08.011
PMid:16316774

 

8. Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, et al. Podoplanin expression during dysplasia–carcinoma sequence in the oral cavity. Tumor Biol. 2012;33:183-94.
https://doi.org/10.1007/s13277-011-0261-7
PMid:22081310

 

9. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 2008;27:127-33.
https://doi.org/10.1111/j.1600-0714.2007.00584.x
PMid:18251935

 

10. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007;96:1-5.
https://doi.org/10.1038/sj.bjc.6603518
PMid:17179989 PMCid:PMC2360213

 

11. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R et al. Podoplanin, novel 43 kDa membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997;151:1141-52.
PMid:9327748 PMCid:PMC1858024

 

12. Raica M, Cimpean AM, Ribatti D. The Role of Podoplanin in Tumor Progression and Metastasis. Anticancer Res. 2008;28:2997-3006.
PMid:19031946

 

13. Franchi A, Gallo O, Massi D, Baroni G, Santucci M. Tumor lymphangiogenesis in head and neck squamous cell carcinoma- a morphometric study with clinical correlations. Cancer 2004;101:973-8.
https://doi.org/10.1002/cncr.20454
PMid:15329906

 

14. Huber GF, Fritzsche FR, Zullig L, Storz M, Graf N, Haerle SK et al. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. Int J Cancer. 2011;129:1404-9.
https://doi.org/10.1002/ijc.25795
PMid:21105028

 

15. Martin –Villair E, Scholl FG, Gamallo C et al. Characterization of human PA2.26 antigen (T1 alpha 2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer. 2005;11:899-910.
https://doi.org/10.1002/ijc.20656
PMid:15515019

 

16. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L. Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008;26:354-60.
https://doi.org/10.1200/JCO.2007.13.4072
PMid:18202409

 

17. Yuan P, Temam S, Naggar AE, Zhou X, Liu DD, Lee JJ, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006;107:563-9.
https://doi.org/10.1002/cncr.22061
PMid:16804930

 

18. Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T,Syafriadi M, et al. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiol. 2011;78:171-80.
https://doi.org/10.1159/000324926
PMid:21613804

 

19. Vormittag L, Thurnher D, Geleff S. Co-expression of bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)therapy. Int J Radiat Oncol Biol Phys. 2009;73:913-18.
https://doi.org/10.1016/j.ijrobp.2008.10.040
PMid:19215825

 

20. Kreppel M, Kreppel B, Drebber U, Wedemayer I, Rothamel D, Zoller JE, et al. Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications. Oral Dis. 2012;18:692-9.
https://doi.org/10.1111/j.1601-0825.2012.01927.x
PMid:22471854

 

21. de Vincent JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica- Fernandez P, Allonca E, Garcia Pedrero JM. Podoplanin expression in oral leukoplakia: tumorigenic role. Oral Oncol. 2013;49:598-603.
https://doi.org/10.1016/j.oraloncology.2013.02.008
PMid:23473850

 

22. Akinyamoju AO, Adeyemi BF, Kolude B, Adisa AO. Histological grading of oral squamous cell carcinoma patients in Ibadan using Bryne's and Broders' grading systems- a comparative study. Afr J Med Med Sci. 2013;42:333-7
PMid:24839737

 

23. Pindborg J, Sirsat S. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol. 1966;22:764.
https://doi.org/10.1016/0030-4220(66)90367-7

PMid:5224185

 

24. Patil A, Patil K, Tupsakhare S, Gabhane M, Sonune S, Kandalgaonkar S. Evaluation of podoplanin in oral leukoplakia and oral squamous cell carcinoma. Scientifica (Cairo). 2015;2015:135298.
https://doi.org/10.1155/2015/135298

PMid:26558136 PMCid:PMC4618324

 

25. Speight PM, Farthing PM, Bouquot JE. The pathology of oral cancer and precancer. Curr Diag Path.1997;3:165-7.
https://doi.org/10.1016/S0968-6053(05)80014-6

 

26. Prasad B, Kashyap B, Babu G, Kumar G, Manyam R. Expression of podoplanin in different grades of oral squamous cell carcinoma. Ann Med Health Sci Res. 2015;5:299-304.
https://doi.org/10.4103/2141-9248.160181
PMid:26229720 PMCid:PMC4512124

 

27. Kreppel M, Scheer M, Drebber U, Ritter L, Zoller JE. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows arch. 2010;456:473-82.
https://doi.org/10.1007/s00428-010-0915-7
PMid:20393745

 

28. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166:913-21.
https://doi.org/10.1016/S0002-9440(10)62311-5

 

29. Margaritescu C, Raica M, Pirici D, Simionescu C, Mogoanta L, Stinga AC, et al. Podoplanin expression in tumor-free resection margins of oral squamous cell carcinomas: an immunohistochemical and fractal analysis study. Histol Histopathol. 2010; 25:701-11.
PMid:20376776

 

30. Miyasaki Y, Okamoto E, Gonzalez- Alva P, Hayashi J, Ishige T, Kikuchi, et al. The significance of podoplanin expression in human inflamed gingiva. J Oral Sci. 2009;51:283-7.
https://doi.org/10.2334/josnusd.51.283

PMid:19550098